Day: May 19, 2022

London, England, May 19, 2022 (GLOBE NEWSWIRE) — Net Savings Link, Inc. (OTC Pink: NSAV), a cryptocurrency, blockchain and digital asset technology company, today announced that its co-majority shareholder, TG Private Equity Inc. (TG), has retired 500 million shares of Series B Preferred Stock that it owned, which is the equivalent of 500 million shares of common stock. The market value of these shares based on yesterday’s closing price is $4,750,000 (USD). The share cancellation was completed by the company’s transfer agent, Pacific Stock Transfer. NSAV and TG enacted this major share retirement in order to have additional shares available for acquisitions, which management believes will enhance shareholder value and keep dilution to a minimum. NSAV has not issued a single share of common stock in 2022. NSAV’s strategy is to use...

Amsterdam, 19 May 2022 – Brunel International N.V. (Brunel; BRNL), a global provider of flexible workforce solutions and expertise, today announced the voting results of the Annual General Meeting of Shareholders (AGM) of 19 May 2022. The AGM approved all voting items that were on the agenda. The shareholders adopted the financial statements for the 2021 financial year and approved the proposal to distribute a dividend of € 0.45 per share for the 2021 financial year. The dividend, less 15% dividend withholding tax, will be made payable as of 15 June 2022 at ABN AMRO Bank N.V. in Amsterdam. The shares will be quoted ex-dividend on the stock exchange of Euronext Amsterdam as of 23 May 2022. The record date is 24 May 2022 after closing of the stock exchange. Peter de Laat is reappointed as a member of the board of directors for a new term...

LONDON and NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) — Navigator Holdings Ltd. (“Navigator”) (NYSE: NVGS), the owner and operator of the world’s largest fleet of handysize liquefied gas carriers, announced today that it will release its results for the three months ended March 31, 2022 after markets close in New York on Monday, May 23, 2022. The next day, Tuesday, May 24, 2022 at 11:00 A.M. E.D.T., the Company’s management team will host a Zoom conference call and slide presentation to discuss the financial results. Zoom Conference Call DetailsParticipants should register for the conference call and slide presentation through the following link:https://us06web.zoom.us/webinar/register/WN_Uw3rM5rWTjuADbUifAa4DA Or join by phone:United States: +1 929 205 6099United Kingdom: +44 330 088 5830 For a full list of US and International numbers...

Intervest realises within its office portfolio in Mechelen, rental agreement extensions with Galapagos and Borealis. The various Intervest sites in Mechelen Noord, strategically located between Antwerp and Brussels, will be renovated in phases over the coming years to create a sustainable cluster of offices.AttachmentPR_Update Rentals Mechelen_EN

The total number of innovative NME cell/gene therapy and non-NME NDAs has risen since 2020 LONDON, May 19, 2022 (GLOBE NEWSWIRE) — In 2021, the FDA approved 122 New Drug Applications (NDAs) and Biologics License Applications (BLAs), including new molecular entities (NMEs), biologics approved as BLAs through the Center for Biologics Evaluation and Research (CBER), and new formulations of older drugs. There were four NME cell/gene therapy approvals in 2021, the highest over the last decade. These include two cell therapies and two gene-modified cell therapies. The New Drug Approvals and Their Contract Manufacture – 2022 Edition report offered by GlobalData Plc analyzes the performance of the pharmaceutical CMO industry, using NDA and BLA approvals by the FDA and new active substance (NAS) approvals by the European Medicines Agency’s...

The neuroimmunology drug development space is dynamic and of high value LONDON, May 19, 2022 (GLOBE NEWSWIRE) — Neuroimmune communication is complex, bidirectional, and mediated across both neural and humoral pathways. A neuroimmunology drug is an agent that aims to regulate immune system activity to treat neurological diseases with underlying immune pathologies. Of the innovator products marketed for the eight key indications covered in this report, the majority are indicated for multiple sclerosis (MS), followed by neuromyelitis optica spectrum disorder (NMOSD), Alzheimer’s disease (AD), and for myasthenia gravis (MG). Most marketed neuroimmunology products are small molecules, followed by mAbs and recombinant proteins. The list of pipeline neuroimmunology therapeutics currently in development is extensive and holds numerous...